CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...
New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...
MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, its small molecule telomere-targeting anticancer agent ...
In this new study, researchers Benigno C. Valdez, Bin Yuan ... of ABT199/venetoclax with the DNA alkylator thiotepa (Thio) in AML cells. The researchers posit, "The results may provide relevant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback